Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Sponsor
Fudan University
Study ID
NCT06355024
Phase
PHASE2
Status
Completed

Conditions

  • Triple-negative Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.

Key Dates

Start date
May 11, 2024
Status verified
Jul 2025
Primary completion
Jan 1, 2025
Completion
Jan 1, 2025

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Inosine
    oral inosine arm

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months ]

Related Studies